News und Analysen
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced
SPAC: Postponement of the General Meeting of Shareholders
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article
CI Financial Announces First Quarter Earnings Conference Call and Webcast
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) will release its financial results for the first quarter of fiscal 2022 on Thursday, May 12, 2022.
CI will hold a conference call with analysts
CI Global Asset Management Announces Launch of ETF Series of CI Floating Rate Income Fund
CI Global Asset Management (“CI GAM”) today announced that ETF C$ Series units of CI Floating Rate Income Fund (the “Fund”) will begin trading today on the Toronto Stock Exchange (“TSX”) under the
Granite REIT Declares Distribution for April 2022
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2583 per stapled unit for the month of
CI Global Asset Management Announces April 2022 Distributions for CI ETFs
CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month ending April 30, 2022 in respect of the CI ETFs. In all cases, the distribution will be paid
Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has exercised its
CI Global Asset Management Completes 27 Mutual Fund and ETF Mergers
CI Global Asset Management (“CI GAM”) announced today it has completed the merger of 21 mutual funds and six exchange-traded funds into other investment funds. The mergers were implemented after
ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today
CI Financial to Hold Annual Meeting of Shareholders on June 22, 2022
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) announced today it will hold its Annual Meeting of Shareholders on Wednesday, June 22, 2022 at 2 p.m. EDT.
The meeting will be held in a
CI Global Asset Management Announces Estimated Reinvested Distributions in Connection with Mergers
CI Global Asset Management (CI GAM) announces the following estimated reinvested distributions (the “Estimated Reinvested Distributions”) in respect of the upcoming mergers of certain funds on or
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
Granite REIT Notice of Conference Call for First Quarter 2022 Results
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) expects to announce its financial results for the first quarter ended March 31, 2022 after the close of markets on
CI Financial to Acquire Former Eaton Vance Investment Counsel Division, Expanding U.S. Wealth Management Strategy
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) today announced an agreement under which CI will acquire certain assets of Eaton Vance WaterOak Advisors, formerly Eaton Vance Investment Counsel
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease
Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for
Leading Northern Ireland Convenience Retailer The Henderson Group Selects GLORY CASHINFINITYTM Solutions As Key Enabler for Store Transformation Programme
Glory (TYO: 6457), a global leader in retail cash automation solutions today announced that major Northern Ireland retailer The Henderson Group, has signed a significant new order with the company
Leading Northern Ireland Convenience Retailer The Henderson Group Selects GLORY CASHINFINITYTM Solutions As Key Enabler for Store Transformation Programme
Glory (TYO: 6457), a global leader in retail cash automation solutions today announced that major Northern Ireland retailer The Henderson Group, has signed a significant new order with the company
Leading Northern Ireland Convenience Retailer The Henderson Group Selects GLORY CASHINFINITYTM Solutions As Key Enabler for Store Transformation Programme
Glory (TYO: 6457), a global leader in retail cash automation solutions today announced that major Northern Ireland retailer The Henderson Group, has signed a significant new order with the company
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
CI Global Asset Management Announces Securityholder Approval of Proposed Mutual Fund and ETF Mergers
CI Global Asset Management (“CI GAM”) announced today that it has received the required securityholder approval to merge 21 mutual funds and six exchange-traded funds.
The mergers were approved
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla